Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Dallas, Texas--(Newsfile Corp. - February 18, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed 57.6% of participants reported perceived improvement in their OSA, and most of those described the change as meaningful to daily life. IHL-42X was well tolerated across both dose cohorts, reinforcing its potential for broad use.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• IHL-42X receives fast track approval
• $68.9M in reported cash & cash equivalents
• Positive Phase 2 results for PSX-001

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
[phone]
[e-mail]

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284430

The Incannex Healthcare Stock at the time of publication of the news with a fall of -6,15 % to 6,71EUR on Nasdaq stock exchange (05. Dezember 2023, 14:49 Uhr).